Gestala Launches Shanghai HQ and Secures Over RMB 420 Million in Series Angel+ Funding to Accelerate Ultrasound-Based Brain-Computer Interface Development

　　【Pharmaceutical Network Corporate News] In recent years, the field of brain-computer interfaces (BCIs) has garnered significant attention. It is reported that on July 3, Gestala Technology, a domestic ultrasonic BCI company, announced the official opening of its Shanghai headquarters in the “Brain-Intelligence World” in Minhang District, while simultaneously completing a RMB 420 million Angel+ round of financing. The company stated that the completion of this funding round and the inauguration of the Shanghai headquarters mark the formal establishment of Gestala Technology’s dual-headquarters strategy (“Chengdu + Shanghai”), as it strives to build a Neolab (frontier laboratory) in the field of brain science.
 

Gestala’s current financing round was led by Huaying Capital, with participation from numerous leading domestic and international investment institutions, including C Capital, Sequoia China, Lens Technology, CECC Health Fund, Sinovation Ventures, Lingang Sci-Tech Innovation Investment, Furong Capital, and Guotai Venture Capital. Existing shareholders, including Daotong Investment, Yunshi Capital, Qingsong Capital, and Gobi Partners, continued to oversubscribe with additional investments. China Renaissance served as the exclusive financial advisor.
 

On March 12 this year, Gestala announced the completion of its RMB 150 million angel financing round, bringing its cumulative funding to RMB 570 million. The company has established a dual-center R&D and innovation system coordinated between Chengdu and Shanghai, rapidly building out its R&D framework, industrial ecosystem, and global talent pool. Its next step is to fully develop “Neolab,” a cutting-edge laboratory in the field of brain science.
 

Neolab represents a cohort of cutting-edge laboratories, including those led by OpenAI, Anthropic, SSI, and AMI, which bring together scientific research and industrial talent. Among them is MergeLabs, an ultrasonic brain-computer interface (BCI) enterprise co-founded by Sam Altman and established in the same month as Gestala Technology. For basic scientific research to transcend the laboratory setting and benefit the general public, a complete industrial translation pipeline is indispensable. To this end, Gestala Technology has built its first ultrasonic BCI super-factory, bridging the critical gap between fundamental research and industrial-scale application.
 

It is reported that on June 26, the completion and operational launch ceremony for Phase I of Gestala’s Global Headquarters and Super Factory was held in Chengdu. Covering a total area of over 16,000 square meters, the facility is an integrated science and technology innovation complex combining headquarters offices, basic scientific research, animal experimentation, frontier product development, and standardized manufacturing. The newly operational super factory features GMP-compliant workshops for the R&D, production, and testing of Class II and Class III active medical devices, along with specialized multi-disciplinary research laboratories.
 

Chengdu’s Global Headquarters is positioned as an R&D and manufacturing center, focusing on the core technology development, clinical translation, and device production of ultrasonic brain-computer interfaces; whereas the newly inaugurated Shanghai Headquarters is positioned as a NeuroAI Innovation Center, prioritizing the development of foundational AI brain models and the integration of global innovation resources, thereby continuously linking worldwide innovative resources in brain science and artificial intelligence. Relevant stakeholders expressed their hope to fully leverage Shanghai’s comprehensive advantages in basic AI research, industrial ecosystem, and international cooperation, so as to promote the deep integration of brain science and artificial intelligence and accelerate the exploration of future-oriented paradigms for human-brain intelligent computing.
 

Data shows that Gestala Technology is committed to building a brain-computer interface (BCI) platform based on ultrasound with whole-brain read-write capabilities. While providing innovative therapies for various neurological disorders, the company further decodes the brain and promotes the deep integration of brain science and artificial intelligence. The company has achieved rapid development, accomplishing in just six months key leaps that traditionally take hard-tech enterprises several years to achieve. This not only demonstrates Gestala Technology’s strategic layout in technology route selection, R&D team building, and industrialization promotion, but also reflects China’s emerging systemic advantages in the BCI field, driven jointly by engineering capabilities, clinical resources, and industrial chain systems.
 

Some investors stated that Gestala has established a super factory for ultrasound brain-computer interfaces (BCIs) in Chengdu, creating an integrated chain from fundamental research to large-scale production. The company is poised to become an influential innovator in the global ultrasound BCI sector. These investors expressed strong confidence in the development prospects of ultrasound BCIs. Looking ahead, with continuous technological iterations and expanding clinical applications, ultrasound BCIs will gradually integrate into public life, driving transformation in healthcare, intelligent technology, and other fields. Meanwhile, domestic enterprises represented by Gestala will continue to propel China’s brain science industry to the forefront.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.